San Diego’s 3D bioprinting firm Organovo Holdings, Inc. announced Wednesday that its subsidiary Samsara Sciences Inc. has officially launched commercial operations.
Samsara will focus solely on providing human liver cells for use in research applications, according to an Organovo news release.
Given the importance of 3D printed liver cells to internal and collaborative operations at Organovo, the company has established Samsara to take care of that aspect of the business exclusively. The company announced that the creation of the subsidiary will optimize the supply chain and operating expenses in the area of cell sourcing.
Samsara will also provide such cells to life science customers through typical commercial channels, according to the release.